Pharmacodynamic effects and mechanisms of resistance to Vemurafenib in patients with metastatic melanoma

- Trunzer, Kerstin, Pavlick, Anna C., Hersey, Peter, Long, Georgina V., Lawrence, Donald, Ott, Patrick A., Amaravadi, Ravi K., Lewis, Karl D., Puzanov, Igor, Lo, Roger S., Koehler, Astrid, Kockx, Mark, Schuchter, Lynn, Spleiss, Olivia, Schell-Steven, Annette, Gilbert, Houston N., Cockey, Louise, Bollag, Gideon, Lee, Richard J., Joe, Andrew K., Sosman, Jeffrey A., Ribas, Antoni, Gonzalez, Rene, McArthur, Grant A., Hutson, Thomas E., Moschos, Stergios J., Flaherty, Keith T., Kim, Kevin B., Weber, Jeffrey S.

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

- Sosman, Jeffery A., Kim, Kevin B., Hersey, Peter, Kefford, Richard, Lawrence, Donald, Puzanov, Igor, Lewis, Karl D., Amaravadi, Ravi K., Chmielowski, Bartosz, Lawrence, H. Jeffrey, Shyr, Yu, Ye, Fei, Schuchter, Lynn, Gonzalez, Rene, Pavlick, Anna C., Weber, Jeffrey S., McArthur, Grant A., Hutson, Thomas E., Moschos, Stergios J., Flaherty, Keith T.

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with Carboplatin and Paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

- Hauschild, Axel, Agarwala, Sanjiv S, Peschel, Christian, Schadendorf, Dirk, Garbe, Claus, O'Day, Steven, Daud, Adil, White, J. Michael, Xia, Chenghua, Patel, Kiran, Kirkwood, John M., Keilholz, Ulrich, Trefzer, Uwe, Hogg, David, Robert, Caroline, Hersey, Peter, Eggermont, Alexander, Grabbe, Stephan, Gonzalez, Rene, Gille, Jens